| name | endo-rtcgm-adip-vs-mdis-smbg-t1d |
| description | The skill suggests using real-time continuous glucose monitoring (CGM) combined with algorithm-driven insulin pumps (ADIPs) rather than multiple daily injections (MDIs) with self-monitoring of blood glucose (SMBG) three or more times daily for adults and children with type 1 diabetes (T1D) to lower hypoglycemia incidence. Clinical triggers include discussions about insulin pump therapy, CGM use, or reducing hypoglycemia in T1D patients on intensive insulin regimens. |
Real-Time Continuous Glucose Monitoring and Algorithm-Driven Insulin Pump vs Multiple Daily Injections with SMBG for Type 1 Diabetes
STEP 1 — Gather Information
Confirm T1D diagnosis, age (adult/child), current insulin regimen (MDI with SMBG ≥3×/day), hypoglycemia history (especially nocturnal/severe), hypoglycemia awareness, patient/family willingness to use devices, insurance/coverage for CGM and pump, baseline HbA1c and time in range, and any contraindications (skin adhesive allergy, device aversion, inability to perform fingersticks).
STEP 2 — Rule In / Rule Out
Is the patient an adult or child with T1D currently on MDI with SMBG ≥3 times daily and seeking to reduce hypoglycemia?
- Yes → Proceed to Step 3.
- No → Consider alternative strategies (e.g., maintain current regimen, evaluate other technologies) and stop.
STEP 3 — Classify or Stratify
Stratify by hypoglycemia awareness: presence of impaired awareness of hypoglycemia (IAH) or significant fear of hypoglycemia vs normal awareness; also consider age group (pediatric <18 years vs adult) for device suitability and education needs.
STEP 4 — Decide
If patient has IAH, high hypoglycemia burden, or simply desires reduction, prescribe real-time CGM + algorithm-driven insulin pump; arrange device training, structured education, and plan for periodic SMBG for calibration/validation; set follow-up to review hypoglycemia incidence and glycemic metrics.
Clinical Guardrails / Mimics / Pitfalls
SMBG remains necessary for calibration, sensor warm-up, and confirming discordant symptoms; do not rely solely on CGM for insulin dosing without confirmation. Avoid in patients with severe skin adhesive reactions, inability to manage device alarms, or unwillingness to perform fingersticks. Ensure structured diabetes education is provided. Be aware of cost and insurance barriers; do not use in acute illness where CGM may be inaccurate (e.g., hypotension, vasoconstriction). Do not discontinue SMBG entirely.
Concrete Clinical Example
A 14-year-old adolescent with T1D on MDI 4×/day reports nocturnal hypoglycemia twice weekly and fears sleeping; after confirming eligibility, the clinician prescribes a real-time CGM integrated with an algorithm-driven insulin pump, provides device training, schedules SMBG for calibration, and at 3‑month follow‑up notes reduced nocturnal hypoglycemia and improved time in range.
Source: Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596
